DecImmune Therapeutics Receives $1M in Equity Financing; $2.2M Phase II SBIR Funding

DecImmune Therapeutics, a Boston, MA-based developer of a technology aimed to reduce tissue damage, accelerate healing, and improve outcomes associated with ischemia reperfusion injury, has received a $1m equity investment as well as a $2.2m Phase II SBIR funding from the National Institutes of Health.
The equity financing was provided by Astellas Venture Management, Amgen Ventures and HealthCare Ventures.
The new funds will support the continued preclinical development of the company’s therapeutic program targeting myocardial salvage. The company received a $1.8m Phase II SBIR grant in 2009 for the study of vascular epitope (N2*) therapeutics for burn wounds.
*The company was founded by Michael Carroll PhD (The Immune Disease Institute, Harvard Medical School), and Francis Moore Jr. MD (Brigham and Women’s Hospital, Harvard Medical School), who discovered the epitope of non-muscle myocin heavy chain II – N2 – that becomes exposed on vascular cells during hypoxia.

Join the discussion